Business Wire

Agendia and Paige Announce Landmark Strategic Partnership to Revolutionize Treatment Planning in Breast Cancer

Share

Agendia, Inc., a world leader in precision oncology for breast cancer, and Paige, a global leader in AI-based digital diagnostics, today announced a first of its kind strategic partnership that will redefine precision oncology. The partnership will enable co-development of treatment planning tools that integrate the cloud-based Paige Platform with genomic information from Agendia’s proprietary MammaPrint® and BluePrint® diagnostic tests for patients with breast cancer. These new products will enable faster access to predictive and prognostic information along the entire continuum of care, from diagnosis and early intervention to metastatic treatment planning.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005250/en/

“Paige’s digital pathology platform is truly transformational for oncology and will catapult diagnostics forward as a whole. This partnership defines the democratization of treatment planning tools by accelerating access to these tests and the essential insights they provide for more patients globally,” said Mark Straley, Chief Executive Officer of Agendia. “Our goal is to provide same-day turnaround in most cases, enable earlier intervention, preserve limited biopsy or surgical tissue specimens, and extend key benefits to physicians and their patients with access to testing in countries where tissue ‘send out’ is not allowed. Whether a patient is in Manhattan or Mumbai, the ability to get real-time and accurate results from Agendia’s MammaPrint and BluePrint tests will improve how we are treating breast cancer today.”

The initial focus of the collaboration will be the development of digital tests for early treatment planning where genomic testing has played an essential role in determining recurrence risk and tumor biology as doctors and their patients make decisions about the path ahead. This can be especially important for patients with operable breast cancer. Beyond early intervention, AI-derived biomarkers will be used to augment genomic testing in the metastatic setting where a multitude of therapeutic options can add to the complexity of treatment planning.

“As the first company to receive FDA clearance, FDA breakthrough designation and two CE marks for digital and computational pathology products, Paige is delivering next-generation digital diagnostics that redefine how we approach cancer care,” said Leo Grady, Ph.D., Chief Executive Officer of Paige. “By combining our unique capabilities with Agendia’s leadership in breast cancer, we believe this innovative partnership can achieve our shared goal of transforming clear and actionable information into precision treatment for better patient outcomes. It will be the first of many AI-based diagnostic tests to come.”

For more information, please visit Agendia.com and Paige.ai.

About Agendia

Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing early stage breast cancer patients and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.

MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.

By developing evidence-based novel genomic tests and conducting groundbreaking research while building an arsenal of data that will help treat breast cancer, Agendia aims to improve patient outcomes and support the evolving clinical needs of breast cancer patients and their physicians every step of the way, from initial diagnosis to cancer-free.

Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com

About Paige

Paige was founded in 2017 by Thomas Fuchs, Dr.Sc. and colleagues from Memorial Sloan Kettering Cancer Center (MSKCC). The company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of AI-based technologies positioned to drive the future of diagnostics, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s products deliver insights to pathologists and oncologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA breakthrough designation for computational pathology products.

For additional information, please visit: https://www.Paige.ai, https://www.paigeplatform.com , Twitter and LinkedIn.

Contact information

For Media:
Terri Clevenger
Westwicke/ICR Healthcare PR
Tel: 203.856.4326
Terri.Clevenger@icrinc.com

For Agendia Investors:
Mike Cavanaugh
Westwicke/ICR Healthcare IR
Tel: 617.877.9641
Mike.Cavanaugh@westwicke.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Tanner Pharma Group Expands Ex-US Access Program to Provide LEUKINE® for Use in Patients with Respiratory Illness Associated with COVID-198.3.2021 16:53:00 CETPress release

Tanner Pharma Group (Tanner) today announced expansion of the LEUKINE Access Program (LeAP) as a channel for distribution of LEUKINE® (sargramostim) in international markets. LEUKINE®, approved by the US FDA in 1991 and now manufactured by Partner Therapeutics (PTx), is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that stimulates the immune system and has been used in leukemia patients to reduce the risk of infection. PTx recently announced that a clinical trial of Leukine® conducted in Belgium of hospitalized COVID-19 patients suffering from acute hypoxic respiratory failure requiring supplemental oxygen met the primary endpoint of significant improvement in lung function. Improvement in oxygenation of at least 33% or more from baseline was seen in 54% of patients on the LEUKINE® plus standard-of-care (SOC) arm versus 26% of patients on SOC (p=.0147). Tanner provides a regulatory-compliant pathway to make LEUKINE® available in international markets. If a pat

H.I.G. Capital Expands European WhiteHorse Team with the Addition of Laurent Vaille and Charles Bourgeois8.3.2021 16:30:00 CETPress release

H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with over €35 billion of equity capital under management, is pleased to announce the expansion of its European WhiteHorse team with the addition of Laurent Vaille and Charles Bourgeois as Principals. Laurent will be based in H.I.G.’s London office, and Charles is based in H.I.G.’s Paris office. Laurent has 13 years of experience in direct lending and corporate finance. He was previously an Executive Director in the Private Debt division of Tikehau Capital in Paris. Prior to that, he worked for Ernst & Young and Deloitte Finance. Charles has 13 years of experience in direct lending and corporate finance. Prior to joining H.I.G., he was an Executive Director in the Private Debt division of Tikehau Capital in Paris. He was previously with GE Capital in the leveraged finance division, after working at SG and LD&A Jupiter. Commenting on the hire, Pascal Meysson, Head of H.I.G. WhiteHorse Europe, said, “Hiring profe

PerkinElmer Adds HPLC Columns to Consumables Portfolio8.3.2021 16:22:00 CETPress release

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that it has added state-of-the-art columns and chemistries to its LC consumables portfolio by acquiring ES Industries, based in West Berlin, New Jersey in the U.S. ES Industries is known for its innovative and highly efficient HPLC and supercritical fluid chromatography (SFC) column chemistries. The team has over 40 years of experience delivering columns with superior reliability, scalability, and reproducibility that are used routinely for method development processes, LC/MS analysis, quality control and preparative purification. Building on PerkinElmer’s https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.perkinelmer.com%2Fcategory%2Fliquid-chromatography-hplc-uhplc-instruments&esheet=52392346&newsitemid=20210308005611&lan=en-US&anchor=recently+announced+LC+300TM+HPLC%2FUHPLC+and+SimplicityChromTM+CDS+solution&index=3&md5=8aaa6199b7c1a347615a2b8ae0dd87b1 recently announ

Veristat Congratulates Origin Biosciences for FDA Approval of Nulibry During the Week of Rare Disease Day 20218.3.2021 15:25:00 CETPress release

Veristat, a scientific-minded, global clinical research organization (CRO), today congratulated Origin Biosciences for their FDA approval of Nulibry (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A. This rare disease product received FDA approval on Friday, 26 February 2021, during the week when the world celebrated #RareDiseaseDay2021. Veristat’s biostatisticians, programmers, and medical writers collaborated with Origin Biosciences to support the New Drug Application (NDA) for Nulibry. The entire Veristat team is honored to know that the hard work and perseverance of the combined Origin/Veristat team brought new hope for children whose lives are shortened by the devastating disease MoCD Type A. “We thank the entire Veristat team who worked diligently to help us bring this critical therapy to patients with no other FDA-approved treatment options,” said Dr. Liza Squires, Origin Chief Medical

CBS News “Global Thought Leaders” Series Features Echosens: Video Showcases FibroScan ® as Medical Gold Standard8.3.2021 15:01:00 CETPress release

Echosens, a high-technology company offering the FibroScan® family of products, is pleased to announce that it has been chosen for the “Global Thought Leaders” series broadcast on CBS News. View a short video highlighting the Company’s groundbreaking work in the development of vital medical resources, including FibroScan®, a noninvasive solution for measuring liver elasticity and fat content of the liver at the point of care. “We’re pleased to be selected by CBS News and proud of the video created at our international headquarters in Paris which captures the essence of Echosens, including interviews with some of our top leaders and a clinician performing a FibroScan® exam with her patient,” says Dominique Legros, Group CEO, Echosens. “Reliable, accurate and affordable, FibroScan® is designed to address a growing liver disease epidemic. Nonalcoholic fatty liver disease (NAFLD) affects approximately 25% of the worldwide population and as many as 6% are affected by NASH, which is expected

Infor and C3 AI Form Strategic Partnership to Deliver Scalable Enterprise AI Industry Applications8.3.2021 15:00:00 CETPress release

C3 AI (NYSE: AI), a leading enterprise AI software provider, and Infor, an ERP technology cloud leader, today announced a wide-ranging strategic alliance designed to jointly expand enterprise-class artificial intelligence (AI) solutions across applicable industries to extend Infor’s native machine learning capabilities. This will allow Infor to explore expansion of its industry offerings into edge scenarios and analyze ways to provide deeper capabilities beyond standard Infor offerings. Infor plans to market, license, and deploy C3 AI prebuilt solutions to Infor customers under the Infor brand and to explore new solutions using the C3 AI® Suite. Infor and C3 AI expect to leverage both companies’ existing digital portfolios to collaborate on new integrated enterprise AI applications that can support specific industry needs. The initial focus will be on predictive maintenance surrounding Internet of Things (IoT) systems with the goal of providing a more proactive and accurate maintenance

NielsenIQ Establishes Independence as a Standalone Company8.3.2021 15:00:00 CETPress release

Today, NielsenIQ begins its next chapter as an independent company with the closing of its acquisition by Advent International in partnership with incoming Executive Chairman and CEO James “Jim” Peck. As a standalone business, NielsenIQ is better positioned to accelerate its transformation and strengthen its market-leading position. To move forward as a definitive leader in the FMCG industry and usher in a new era of technological advancements and innovation, three new leaders will join NielsenIQ. Mohit Kapoor joins as Chief Technology Officer, overseeing all aspects of technology. Steve Matthesen, a Nielsen veteran, joins as Chief Strategy Officer to help develop and execute the corporate strategy and other key initiatives. Curt Miller joins as Chief Transformation Officer to drive organizational alignment that supports NielsenIQ’s growth strategy. “NielsenIQ has a unique opportunity to become a nimble partner with the flexibility to increase strategic investments and innovation in th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom